Sprint Bioscience AB Asset Resilience Ratio

Latest as of September 2022: 77.81%

Sprint Bioscience AB asset resilience ratio. Sprint Bioscience AB (SPRINT) has an Asset Resilience Ratio of 77.81% as of September 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Sprint Bioscience AB defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Liquid Assets

Skr26.73 Million
≈ $2.88 Million USD Cash + Short-term Investments

Total Assets

Skr34.35 Million
≈ $3.70 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of Sprint Bioscience AB (2016–2017)

Asset resilience ratio of Sprint Bioscience AB from 2016 to 2017. This chart shows how Sprint Bioscience AB's Asset Resilience Ratio has changed over time. Read Sprint Bioscience AB (SPRINT) financial obligations for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Sprint Bioscience AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Sprint Bioscience AB.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Skr26.73 Million 77.81%
Short-term Investments Skr0.00 0%
Total Liquid Assets Skr26.73 Million 77.81%

Asset Resilience Insights

  • Very High Liquidity: Sprint Bioscience AB maintains exceptional liquid asset reserves at 77.81% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Sprint Bioscience AB Industry Peers by Asset Resilience Ratio

Compare Sprint Bioscience AB's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Hyloris Developmentsen Sa
BR:HYL
Biotechnology 1.36%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Oruka Therapeutics, Inc.
NASDAQ:ORKA
Biotechnology 53.11%
Gempharmatech Co. Ltd. A
SHG:688046
Biotechnology 23.95%
Vor Biopharma Inc
NASDAQ:VOR
Biotechnology 74.48%
Inventiva S.A
PA:IVA
Biotechnology 52.73%
Sunmax Biotechnology Co Ltd
TWO:4728
Biotechnology 10.53%
Guangdong VTR Bio-Tech Co Ltd
SHE:300381
Biotechnology 4.98%

Sprint Bioscience AB Asset Resilience Ratio by Year (2016–2017)

Sprint Bioscience AB asset resilience ratio by year from 2016 to 2017. The table below shows the annual Asset Resilience Ratio data for Sprint Bioscience AB.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2017-12-31 4.17% Skr1.48 Million
≈ $159.16K
Skr35.48 Million
≈ $3.82 Million
-43.50pp
2016-12-31 47.67% Skr23.61 Million
≈ $2.54 Million
Skr49.52 Million
≈ $5.33 Million
--
pp = percentage points

About Sprint Bioscience AB

ST:SPRINT Sweden Biotechnology
Market Cap
$38.95 Million
Skr361.92 Million SEK
Market Cap Rank
#22613 Global
#426 in Sweden
Share Price
Skr3.43
Change (1 day)
+2.08%
52-Week Range
Skr0.64 - Skr4.49
All Time High
Skr47.75
About

Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of drug candidates to treat cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; DCPS which is in preclinical trial for the treatment of acute myeloid leukemia; VRK1, which is in preclinical development to treat solid tumors; VPS34, a d… Read more